Cargando…

The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms

Advanced hepatocellular carcinoma (HCC) is a formidable public health problem with limited curable treatment options. Axitinib, an oral tyrosine kinase inhibitor, is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2, and 3. This anti-angio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Hao, Liao, Jian, Wang, Liezhi, Jin, Chong, Mo, Jinggang, Xiang, Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264605/ https://www.ncbi.nlm.nih.gov/pubmed/37325670 http://dx.doi.org/10.3389/fimmu.2023.1163967

Ejemplares similares

Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
por: Zhao, Shankun, et al.
Publicado: (2021)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
por: Bæk Møller, Nanna, et al.
Publicado: (2019)

Multikinase inhibitor-based immunotherapy doublet for advanced hepatocellular carcinoma: its efficacy still needs to be determined
por: Li, Heming, et al.
Publicado: (2023)

Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
por: Pan, Hongming, et al.
Publicado: (2014)

Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
por: Wang, Kunpeng, et al.
Publicado: (2021)

Roles of hypoxia-inducible factor in hepatocellular carcinoma under local ablation therapies
por: Xiao, Chunying, et al.
Publicado: (2023)

Treatment outcomes of advanced hepatocellular carcinoma in real‐life practice: Chemotherapy versus multikinase inhibitors
por: Oranratnachai, Songporn, et al.
Publicado: (2022)

Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib
por: Horger, Marius, et al.
Publicado: (2009)

Author Correction: Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib
por: Pan, Hongming, et al.
Publicado: (2020)

Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
por: Shimose, Shigeo, et al.
Publicado: (2020)

Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma
por: Miller, Kevin C, et al.
Publicado: (2020)

Neoadjuvant Multikinase Inhibitor in Patients With Locally Advanced Unresectable Thyroid Carcinoma
por: Nava, Carla Fernanda, et al.
Publicado: (2019)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
por: Oranratnachai, Songporn, et al.
Publicado: (2021)

Axitinib Reverses Resistance to Anti-Programmed Cell Death-1 Therapy in a Patient With Renal Cell Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

PIK3R3 is upregulated in liver cancer and activates Akt signaling to control cancer growth by regulation of CDKN1C and SMC1A
por: Lin, Weidong, et al.
Publicado: (2023)

Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial
por: Yang, Kai-Lin, et al.
Publicado: (2021)

Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach
por: Alqahtani, Saleh A., et al.
Publicado: (2020)

Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report
por: Endo, Yutaka, et al.
Publicado: (2022)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
por: Colombo, Carla, et al.
Publicado: (2022)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma
por: Zhao, Ming, et al.
Publicado: (2023)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

The mechanism of flavonoids from Cyclocarya paliurus on inhibiting liver cancer based on in vitro experiments and network pharmacology
por: Mo, Jinggang, et al.
Publicado: (2023)

Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012)

Exploring Selectivity of Multikinase Inhibitors across the Human Kinome
por: Miljković, Filip, et al.
Publicado: (2018)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Timing of multikinase inhibitor initiation in differentiated thyroid cancer
por: Brose, Marcia S, et al.
Publicado: (2017)

Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma
por: Xie, Fucun, et al.
Publicado: (2022)

Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
por: Shigesawa, Taku, et al.
Publicado: (2020)

Higher Number of Tumor-Infiltrating PD-L1+ Cells Is Related to Better Response to Multikinase Inhibitors in Hepatocellular Carcinoma
por: Han, Ji Won, et al.
Publicado: (2023)

A novel immune-related genes prognosis biomarker for hepatocellular carcinoma
por: Wang, Kunpeng, et al.
Publicado: (2020)

A Phase II Study of the Multikinase Inhibitor Ponatinib in Patients With Advanced, RET-Rearranged NSCLC
por: Gainor, Justin F., et al.
Publicado: (2020)

Multikinase Inhibitor Treatment Patterns for Advanced Thyroid Cancer in Japan: An Administrative Claims Database Study
por: Masaki, Chie, et al.
Publicado: (2022)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_u9lnfsasrmd32ds672qa4dj7ik